London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Abcam definitely to high for me, so back into GlaxoSmithKline then back in horizon on a decent drop.
That’s £2 gone. Didn’t even stop to test any resistance straight thro. What prizes for guessing a bid price this time. I reckon north of £2.80. No maths just think it’s due a premium on recent highs. Trek.
Still small investors so hopefully get a correction.
Way to high for my liking. Just hopes it drop by sep 8th. Otherwise I’m back into Abcam or might split between them.
I have the same plans haha
I expect earnings ahead of guidance and gearing reduced on back of cash call. Co will be putting up a defence. I expect another bid after results. Trek.
I am expecting a price drop on September 8th, as the company will be reporting negative EBITA. This was hilighted in the last report and the market doesn’t like negative , then I will be back in, that’s the plan anyway.
Good company with very good upside for the future.
I held these for a long time & made a small profit. Decided to wait & hope they fell back to the £1.50 mark & come back in. Cant see that happening now, wish i had stayed invested as other trades in FOOT & BHRD have came a cropper
Clawing its way back to £2. 2 steps forward one back.... will get there eventually. Not long now before the vultures appear with something a little more sensible. £2.80 should do it as the market doesnt attribute fair value to AIM until its sold. Trek.
Pretty impressive... the rest is a mission statement......
Group Financials
The Group expects to report H1 2018 revenues of approximately £25.1 million (H1 2017: £12.1 million), £27.3 million on a constant currency basis, in line with Board expectations. This represents growth of 107% against the equivalent prior period, 126% on a constant currency basis. Revenues on a like-for-like basis (pre-acquisition of Dharmacon) are expected to be approximately £11.1 million (H1 2017: 12.1 million), £12.0 million on a constant currency basis. We expect revenues to be second half weighted, consistent with previous years, and exceed consensus for FY 2018.
Trek
I just added 500 shares here and SP immediately ticked up 1.44p from unchanged. Very thin market. Trek accumulating and waiting.
Next results are in September or November. I will buy back in when sp drops a bit very good prospects and expect Abcam to make another offer . I also expect horizon to go the same as oxford bio sp over a few years.
Wat forward is amore targeted medication based on DNA footprint rather than current broad brush approach. Helps mitigate side effects, efficacy and accuracy plus saves money. HZD should do well out of that thinking if they are around long enough! Trek
Share price reaction to recent news that there appears to be some connection between gene editing and cancer appearing is interesting. As this outcome is disputed perhaps it poo ts to a requirement for greater rigour in research via HZD tools
I am looking forward to next results as I expect they will be good , based on the last results.
I am not clear why Disley left abruptly. He has received a full years salary plus pension etc, according to the Annual Report, quoted in today's Sunday Times. Was he pushed? i cannot see a reason for this, in a thriving company, unless he resigned / was pushed over differences in the direction of travel of the company. The ST article is coy, but does mention the business 'refocusing' on its core products, and that it would reduce the level of investment in its own therpies. Perhaps Disley felt strongly about this - who knows? i think there is probably quite a close (aka incestuous) relationship between individuals in ABCAM and Horizon, even after J Milner's resignation. Whether this is in the best interests of Horizon is far from clear. However, the appointment of Pizzie, with a commercial rather than a scientific background is no bad thing at this stage for Horizon.
Agree with you regarding fca. As for another offer, pretty sure Abcam would need to wait 6 months now before they are eligable to make another offer. Totally guessing, but i would not be surprised if they pulled out because of Milner.
You may be right about him walking but is it not more so the the FCA should be walking. Seems to me that they are far from being sqeaky clean. I have a fair bit in Abcam which I think are a very solid company as soon as horizon go into the black then I will buy but not before. Unless they are approached by Abcam again which I think may happen.
Milner should have walked months ago. I find it impossible to believe that he did not know what was proposed by ABCAM. I have doubts therefore as to the propriety of recent share purchases.
Possible. I did wonder that myself. They may wait now though. Suppose only time will tell.
With no conflict now, will Abcam adopt an aggressive stance re another bid for Horizon , or is that well in the past ?
Saw that coming a couple of weeks ago.
Delighted to hear they have backed off. It was an opportunistic bid, and was correctly rejected. HZD will do very well without them.
Even I thought that Abcam would be a possible suitor a long time ago. Worth noting that management have previously piled in when the shares have gam fallen sharply. They know the value of the business more than most so it is good to see them getting involved. If the offer is successfully rebuffed because they feel they can realise better value independently then he could hardly be accused
Lets face it, if you were abcam ceo and you were interested in buying hzd, you would find out everything possible about hzd and that would include asking dr milner about it. He may well of been left out of the meetings by both companies, but he would of known abcam were interested in buying hzd. His second buy was 13 days before the offer was made and in total both amounts of share bought was shy of 1 million pounds.